The possible future roles for IPSC-Derived therapy for Autoimmune Diseases.

Data de publicació

2017-01-11T14:58:11Z

2017-01-11T14:58:11Z

2015-05-28

2017-01-11T14:58:11Z

Resum

The ability to generate inducible pluripotent stem cells (iPSCs) and the potential for their use in treatment of human disease is of immense interest. Autoimmune diseases, with their limited treatment choices are a potential target for the clinical application of stem cell and iPSC technology. IPSCs provide three potential ways of treating autoimmune disease; (i) providing pure replacement of lost cells (immuno-reconstitution); (ii) through immune-modulation of the disease process in vivo; and (iii) for the purposes of disease modeling in vitro. In this review, we will use examples of systemic, system-specific and organ-specific autoimmunity to explore the potential applications of iPSCs for treatment of autoimmune diseases and review the evidence of iPSC technology in auto-immunity to date.

Tipus de document

Article


Versió publicada

Llengua

Anglès

Publicat per

MDPI

Documents relacionats

Reproducció del document publicat a: https://doi.org/10.3390/jcm4061193

Journal of Clinical Medicine, 2015, vol. 4, num. 6, p. 1193-1206

https://doi.org/10.3390/jcm4061193

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

cc-by (c) Hew, Meilyn et al., 2015

http://creativecommons.org/licenses/by/3.0/es

Aquest element apareix en la col·lecció o col·leccions següent(s)